RBD-12GS-I53-50
A candidate SARS-CoV-2 vaccine.
General information
RBD-12GS-I53-50 is a candidate vaccine. It uses the SARS-CoV-2 spike protein RBD residues 328–531 as an immunogen multivalently displayed on "I53-50" protein nanoparticle (Walls et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Spike protein Protein factor Animal model In vitro Mixed substance |
BALB/c mice; Kymab Darwin mice; pigtail macaque | 38.64 | Elicited significantly stronger antibody (anti-spike and neutralizing) responses in mice and pigtail macaques, especially after second immunization, compared to RBD or spike trimer vaccination only. The antibody response was targeting non-overlaping RBD sites. The vaccine candidate provided protection from mouse-adapted SARS-CoV-2 in murine lungs and nasal turbinates. |
Oct/30/2020 |
